Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zeleciment Basivarsen · DYNE-101

Oligonucleotide (Antisense oligonucleotide) · developed by Dyne Therapeutics

Phase 3 Most advanced trial

DYN Developer

2 Registered trials

What is Zeleciment Basivarsen?

Zeleciment basivarsen (DYNE-101) is administered by intravenous infusion. It is studied in myotonic dystrophy type 1.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: DYNE-101
Drug type: Oligonucleotide (Antisense oligonucleotide)
Therapy area: Neurology
Developer: Dyne Therapeutics (DYN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: T7PH26YY2C

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07486934	Phase 3	Myotonic Dystrophy Type 1 (DM1)	Recruiting	DYN
NCT05481879	Phase 1/2	Myotonic Dystrophy Type 1 (DM1)	Active not recruiting	DYN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DM1Myotonic DystrophyMyotonic Dystrophy Type 1 (DM1)SteinertSteinert Disease

More from Dyne Therapeutics

Zeleciment Rostudirsen Phase 3

Sources

ClinicalTrials.gov NCT05481879

Updated Oct 11, 2026. Something wrong or missing? Report it on the DYN page.

Follow DYN, the company behind Zeleciment Basivarsen

See DYN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DYN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z